GlassScriptPhysician profile
Brian Dewayne Frank
NPI 1871142687
$3,972.23
in general payments reported to CMS, 2019-2025
18 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.71 · 2022: $154 · 2023: $802 · 2024: $1,153 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.48 |
| Education | $145.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,207.71 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $645.69 | 2022-2025 | Caplyta |
| Alkermes, INC. | $431.15 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $279.24 | 2022-2025 | |
| Axsome Therapeutics, INC. | $205.82 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $204.40 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $189.35 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $157.41 | 2024-2025 | Cobenfy |
| Indivior INC. | $130.19 | 2023-2024 | Perseris |
| Janssen Pharmaceuticals, INC | $113.18 | 2023-2025 | Invega, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $95.31 | 2022 | |
| Lundbeck LLC | $87.15 | 2024-2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $58.63 | 2025 | Jornay Pm |
| Biogen, INC. | $45.61 | 2025 | Zurzuvae |
| Otsuka America Pharmaceutical, INC. | $38.94 | 2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $31.81 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $31.42 | 2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $19.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.